Bañares Virginia, Martini Javier, López Graciela, Corral Pablo, Schreier Laura
Administración Nacional de Laboratorios e Institutos de Salud "Dr Carlos Malbrán", Centro Nacional de Genética Médica, Departamento de Genética Experimental, Ciudad Autónoma de Buenos Aires.
Administración Nacional de Laboratorios e Institutos de Salud "Dr Carlos Malbrán", Centro Nacional de Genética Médica, Departamento de Genética Clínica, Ciudad Autónoma de Buenos Aires.
Gac Med Mex. 2024;160(4):413-419. doi: 10.24875/GMM.M24000918.
LDL-cholesterol greater than 190 mg/dL indicates severe hypercholesterolemia (HS) of monogenic and/or polygenic origin. Genetic risk scores (GRS) evaluate potential polygenic causes.
we applied a GRS of 6-SNP (GRS-6) in HS individuals.
69 subjects from the Familial Hypercholesterolemia (HF) Detection registry in Argentina (Da Vinci).
with 44 individuals with HF-phenotype, not carriers of genetic variants that indicate a monogenic origin (HF/M-) and 26 controls, the GRS-6 cut-off value was established, > 0.76, sensitivity 0.59, specificity 0.69. 15/44(34 %) HF/M- presented GRS-6+. The mean GRS-6 values in HF/M-, HF/M+ and controls were 0.72 ± 0.17, 0.66 ± 0.17, and 0.70 ± 0.13 respectively (p = 0.43). There were no significant differences in cholesterol values, or in the clinical score, between cases with positive vs negative GRS-6. The GRS-6 was positive in 32 % of the cases vs 20 % of the previously applied GRS-10 (p = 0.003), significantly increasing the detection of polygenic contribution.
We present an estimate of the first cut-off value for the GRS-6 in a Latin American population, and we conclude that the GRS-6 could contribute to the evaluation of the polygenic contribution in cases with severe hypercholesterolemia in our population in a similar way to that of other European populations.
低密度脂蛋白胆固醇大于190mg/dL表明存在单基因和/或多基因来源的严重高胆固醇血症(HS)。遗传风险评分(GRS)评估潜在的多基因病因。
我们在HS个体中应用了6个单核苷酸多态性的遗传风险评分(GRS-6)。
来自阿根廷家族性高胆固醇血症(HF)检测登记处(达芬奇)的69名受试者。
44名具有HF表型的个体,不是表明单基因来源的遗传变异携带者(HF/M-),以及26名对照,确定了GRS-6的临界值,>0.76,敏感性0.59,特异性0.69。15/44(34%)的HF/M-表现为GRS-6阳性。HF/M-、HF/M+和对照组的GRS-6平均值得分分别为0.72±0.17、0.66±0.17和0.70±0.13(p=0.43)。GRS-6阳性与阴性的病例在胆固醇值或临床评分上没有显著差异。GRS-6在32%的病例中呈阳性,而之前应用的GRS-10在20%的病例中呈阳性(p=0.003),显著增加了多基因贡献的检测率。
我们给出了拉丁美洲人群中GRS-6的首个临界值估计,并且得出结论,GRS-6可以以与其他欧洲人群类似的方式,有助于评估我们人群中严重高胆固醇血症病例的多基因贡献。